Amicus Therapeutics Inc

FOLD

Equity

ISIN US03152W1099 / Valor 2644388

NASDAQ (2024-09-18)

USD 10.91-2.59%

Amicus Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Amicus Therapeutics Inc is a biotechnology company that focuses on developing therapies for rare and orphan diseases, particularly lysosomal storage disorders.

Summarized from source with an LLMView SourceSector: Healthcare

Total Revenue

Amicus Therapeutics Inc. reported total revenue of $399.4 million for the full-year 2023, marking a 21% increase compared to the previous year. This growth reflects operational expansion and a favorable currency impact of $2.7 million.

Galafold Sales

Galafold (migalastat) net product sales for the full-year 2023 were $387.8 million, representing an 18% year-over-year increase. The fourth quarter alone saw net product sales of $106.6 million, driven by strong patient demand.

Pombiliti + Opfolda Sales

Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) net product sales for the full-year 2023 were $11.6 million. The fourth quarter contributed $8.5 million to this total, reflecting the successful commercial launch in key markets.

Net Loss

On a GAAP basis, Amicus Therapeutics Inc. reported a net loss of $151.6 million for the full-year 2023, which was a reduction from the $236.6 million net loss reported in 2022. The company achieved non-GAAP profitability in the fourth quarter of 2023 with a net income of $2.6 million.

2024 Financial Outlook

For the full-year 2024, Amicus Therapeutics Inc. projects Galafold revenue growth between 11% and 16% at constant exchange rates. The company also anticipates achieving full-year non-GAAP profitability, driven by continued demand and successful product launches.

Summarized from source with an LLMView Source

Key figures

-15.3%1Y

-0.82%3Y

14.1%5Y

Performance

43.7%1Y

49.7%3Y

57.0%5Y

Volatility